22:00 , Jul 11, 2019 |  BC Innovations  |  Product Development

How Zymeworks aims to take on Roche’s $10B HER2 franchise

Zymeworks is going head to head with one of the biggest commercial cancer franchises -- Roche’s Herceptin trastuzumab and Perjeta pertuzumab -- as it pursues clinical proof-of-concept for its protein engineering platform. Pivotal readouts in...
22:39 , Jul 9, 2019 |  BC Extra  |  Company News

July 9 Company Quick Takes: Celgene, Nimbus expand deal; plus Gilead-Lyndra, Darzalex and more

Celgene gets option for Nimbus' HPK1 program  Celgene Corp. (NASDAQ:CELG) expanded its partnership with Nimbus Therapeutics LLC (Cambridge, Mass.) to include an option for the latter's HPK1 inhibitor to treat cancer, which Celgene can exercise...
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
23:41 , Jun 28, 2019 |  BC Extra  |  Financial News

June 28 Financial Quick Takes: Karuna rises after IPO; plus Chi-Med, BeiGene and more

Karuna spikes in first-day trading on NASDAQ  PureTech Health plc (LSE:PRTC) portfolio company Karuna Therapeutics Inc. (NASDAQ:KRTX) climbed $4.02 (25%) to $20.02 Friday after raising $89.2 million through the sale of 5.6 million shares at...
23:45 , Jun 19, 2019 |  BC Extra  |  Clinical News

June 19 Clinical Quick Takes: G1 jumps on breast cancer data; plus Linzess, Lokelma, Boehringer/OSE, GCAR and more

G1 rises on trilaciclib OS efficacy in Phase II for TNBC  G1 Therapeutics Inc. (NASDAQ:GTHX) has gained 33% to $26.27 since reporting preliminary data Tuesday from a Phase II trial showing a statistically significant improvement...
23:53 , Jun 18, 2019 |  BC Extra  |  Company News

BeiGene, SpringWorks form MapKure to develop BRAF inhibitor

Nine months after partnering to test a BRAF-MEK combination therapy, BeiGene and Pfizer spinout SpringWorks are collaborating again, this time forming a joint venture to develop a BeiGene BRAF inhibitor that could lead to combination...
23:43 , Jun 17, 2019 |  BC Extra  |  Company News

BeiGene exploring commercialization options for returned PD-1 inhibitor

After regaining global rights to PD-1 inhibitor tislelizumab from Celgene, BeiGene is exploring options to commercialize the asset on its own or find a partner for the product in the U.S., Europe and Japan. The...
23:50 , Jun 14, 2019 |  BC Extra  |  Clinical News

June 14 Clinical Quick Takes: Chi-Med, BeiGene, UCB, Global Blood and more

Chi-Med’s surufatinib meets in Phase III for extra-pancreatic neuroendocrine tumors  Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) said it is planning a pre-NDA meeting with China’s National Medical Products Administration (NMPA) after surufatinib (formerly sulfatinib) met...
00:36 , Jun 8, 2019 |  BioCentury  |  Product Development

ASCO 2019 sessions provide guidance on expanding patient pools for clinical trials

Two sessions at this year's American Society of Clinical Oncology meeting gave drug developers a glimpse of how to match more patients to clinical trials by broadening eligibility criteria and encouraging trial enrollment in community...
22:20 , May 31, 2019 |  BC Extra  |  Company News

May 31 Company Quick Takes: NMPA accepts two BeiGene applications, approves Hengrui's PD-1 inhibitor; and more

NMPA accepts applications for BeiGene's tislelizumab, Abraxane  China's National Medical Products Administration has accepted an sNDA from BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) for tislelizumab to treat previously treated, locally advanced or metastatic urothelial carcinoma. The anti-PD-1...